Home/Pipeline/S-oxprenolol (ACM-002)

S-oxprenolol (ACM-002)

Muscle optimisation in obesity

Clinical (Phase unspecified)Active

Key Facts

Indication
Muscle optimisation in obesity
Phase
Clinical (Phase unspecified)
Status
Active
Company

About Actimed Therapeutics

Actimed Therapeutics is a clinical-stage biotech pioneering treatments for cachexia and muscle wasting, a high-unmet-need area with no approved therapies. The company has a focused pipeline led by two clinical-stage assets, S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), repurposed enantiomers of existing beta-blockers. Recent strategic moves include a licensing agreement with Mankind Pharma and active data presentations at key medical conferences, positioning the company for potential partnerships and clinical advancement in a significant market opportunity.

View full company profile